- Dosing patients in both MAGE-A10 pilot studies in third cohort with range of one to six billion cells -
- NY-ESO program transitioned to GSK allows clinical focus on wholly owned assets -
- Guidance confirmed, funded through to early 2020 -
- Conference call to be held today at 8:00 a.m. EDT (1:00 p.m. BST) -
PHILADELPHIA and OXFORD, United Kingdom, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today reported financial results for the second quarter ended June 30, 2018, and provided a business update.
“2018 is a year of delivery for Adaptimmune,” said James Noble, Adaptimmune’s CEO. “We have completed multiple studies with the NY-ESO program, and released data showing responses in a second solid tumor. We have transitioned it to GSK as planned and will shortly be receiving payment of $27 million. We are now entirely focused on our wholly owned INDs, and remain on track to deliver initial response data from our MAGE-A10 and MAGE-A4 programs in the second half of 2018.”
Clinical momentum in wholly owned programs
Adaptimmune will now focus its clinical, regulatory, and manufacturing organization on its wholly owned therapies - MAGE-A4, MAGE-A10, and AFP
- Dosing at one billion or more SPEAR T-cells across all studies with MAGE-A10 and MAGE-A4, and on track for response readouts from multiple solid tumors throughout the remainder of 2018.
- Initial safety data from AFP in hepatocellular carcinoma also on track for late 2018.
NY-ESO program transitioned to GSK
- As announced on July 24, 2018 (https://bit.ly/2LKhSvm), the NY-ESO SPEAR T-cell program has transitioned to GSK.
- Adaptimmune will receive $27.5 million (£21.2 million) from GSK as a result of the transition, as well as subsequent development and sales milestones and royalties based on successful development by GSK of this program.
Adaptimmune is increasing the capacity of its dedicated manufacturing facility
- Routinely manufacturing SPEAR T-cells at the Navy Yard at target cell doses
- Developing the capability at the Navy Yard to scale up to 30 manufacturing slots per month from the current number of 8 to 10 per month
- Maintaining 8 to 10 dedicated patient manufacturing slots per month at HCAT
Other corporate news
Adaptimmune is focused on its next stage of development and in a strong position to deliver success with SPEAR T-cell therapies
- Rafael Amado, Adaptimmune’s Chief Medical Officer, has assumed a new role as President of Research & Development effective from August 1, 2018. This brings together the clinical and research teams under a single leadership, which will allow better alignment and integration of all parts of R&D, from target identification and selection, to regulatory filings, enabling the delivery of Adaptimmune’s key priorities.
- Adaptimmune is ready for the next stage of clinical development and actively planning for registration trials, whether indication or target specific
- Funded through to early 2020 with cash and cash equivalents of $42.3 million and total liquidity1 of $129.0 million, which does not include $27.5 million in payments from GSK as a result of the transition as this was invoiced after the second quarter
- Announced in April 2018 (https://bit.ly/2v7v3D3) that John Furey, Chief Operating Officer at Spark Therapeutics, was appointed as an independent Non‑Executive Director to Adaptimmune’s Board of Directors, which became effective July 5, 2018
Financial Results for the three-month period ended June 30, 2018
- Cash / liquidity position: As of June 30, 2018, Adaptimmune had cash and cash equivalents of $42.3 million and Total Liquidity1 of $129.0 million, which does not include $27.5 million in payments from GSK as a result of the transition as this was invoiced after the second quarter
- Revenue: With effect from January 1, 2018, the Company has adopted a new accounting standard2. Under this new accounting standard, revenue represents the upfront payment and milestones under the GSK Collaboration and License Agreement, which are recognized based on the percentage completion of the NY-ESO and PRAME development programs. Revenue for the three and six months ended June 30, 2018 was $9.0 million and $17.2 million, respectively. Revenue for the three and six months ended June 30, 2018 under the previous guidance would have been $3.3 million and $12.3 million, respectively, compared to $3.5 and $6.4 million for the same periods of 2017. The increase in revenue, compared to the six-month period in 2017, is primarily due to a reduction in the period over which the Company is recognizing revenue following GSK’s exercise of its option over the NY-ESO program in September 2017 and additional development milestones achieved.
- Research and development (“R&D”) expenses: R&D expenses for the three and six months ended June 30, 2018 were $26.7 million and $52.0 million, respectively, compared to $19.6 million and $38.2 million for the same periods of 2017. The increase was primarily due to increased costs associated with clinical trials, manufacturing for clinical trials, and increased personnel costs.
- General and administrative (“G&A”) expenses: G&A expenses for the three and six months ended June 30, 2018 were $11.3 million and $22.5 million, respectively, compared to $7.7 million and $14.2 million for the same periods of 2017. The increase was primarily due to increased personnel costs consistent with the Company’s planned growth, an increase in costs associated with developing its IT infrastructure and an increase in other corporate costs.
- Other (expense) income, net: Other expense for the three and six months ended June 30, 2018 was $15.4 million and $8.3 million, respectively, compared to an income of $3.2 million and $3.7 million for the same periods of 2017. Other income primarily comprises unrealized foreign exchange gains, which fluctuate depending on exchange rate movements and the amount of foreign currency assets and liabilities.
- Net loss: Net loss attributable to holders of the Company’s ordinary shares for the three and six months ended June 30, 2018 was $43.8 million and $64.6 million respectively ($(0.08) and $(0.11) per ordinary share) compared to $20.2 million and $42.0 million ($(0.04) and $(0.09) per ordinary share) in the same periods of 2017.
The Company believes that its existing cash, cash equivalents, marketable securities and income from GSK upon transition of the NY-ESO program will fund the Company’s current operations through to early 2020.
1 Total liquidity is a non-GAAP financial measure, which is explained and reconciled to the most directly comparable financial measures prepared in accordance with GAAP below.
2 ASC 606, Revenue from Contracts with Customers.
Conference call information
The Company will host a live teleconference and webcast to provide additional details at 8:00 a.m. EDT (1:00 p.m. BST) today, August 2, 2018. The live webcast of the conference call will be available via the events page of Adaptimmune’s corporate website at www.adaptimmune.com. An archive will be available after the call at the same address. To participate in the live conference call, please dial (833) 652-5917 (U.S.) or +1 (430) 775-1624 (International). After placing the call, please ask to be joined into the Adaptimmune conference call and provide the confirmation code (8149978).
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP across several solid tumor indications. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on May 9, 2018, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward‑looking statements to reflect subsequent events or circumstances.
Total liquidity (a non-GAAP financial measure)
Total Liquidity is the total of cash and cash equivalents, and marketable securities. Each of these components appears in the Consolidated Balance Sheet. The U.S. GAAP financial measure most directly comparable to Total Liquidity is cash and cash equivalents as reported in the Consolidated Financial Statements, which reconciles to Total Liquidity as follows:
|June 30, |
|December 31, |
|Cash and cash equivalents||$||42,312||$||84,043|
The Company believes that the presentation of Total Liquidity provides useful information to investors because management reviews Total Liquidity as part of its management of overall liquidity, financial flexibility, capital structure and leverage.
|Condensed Consolidated Statement of Operations|
|(unaudited, in thousands, except per share data)|
|Three months ended |
|Six months ended |
|Research and development||(26,624||)||(19,591||)||(52,016||)||(38,206||)|
|General and administrative||(11,291||)||(7,710||)||(22,495||)||(14,173||)|
|Total operating expenses||(37,915||)||(27,301||)||(74,511||)||(52,379||)|
|Other (expense) income, net||(15,406||)||3,224||(8,276||)||3,654|
|Loss before income taxes||(43,743||)||(20,050||)||(64,354||)||(41,601||)|
|Net loss attributable to ordinary shareholders||$||(43,845||)||$||(20,215||)||$||(64,583||)||$||(41,997||)|
|Net loss per ordinary share|
|Basic and diluted||$||(0.08||)||$||(0.04||)||$||(0.11||)||$||(0.09||)|
|Weighted average shares outstanding:|
|Basic and diluted||565,197,217||556,776,430||563,804,832||493,392,465|
|Condensed Consolidated Balance Sheets|
|(unaudited, in thousands)|
|December 31, |
|Cash and cash equivalents||$||42,312||$||84,043|
|Marketable securities - available-for-sale debt securities||86,716||124,218|
|Accounts receivable, net of allowance for doubtful accounts of $- and $-||-||206|
|Other current assets and prepaid expenses (including current portion of clinical materials)||32,626||21,716|
|Total current assets||161,654||230,183|
|Property, plant and equipment, net||39,472||40,679|
|Liabilities and stockholders’ equity|
|Accrued expenses and other accrued liabilities||21,457||27,201|
|Total current liabilities||42,310||74,314|
|Other liabilities, non-current||3,887||3,849|
|Common stock - Ordinary shares par value £0.001, 701,103,126 authorized and 566,496,400 issued and outstanding (2017: 701,103,126 authorized and 562,119,334 issued and outstanding)||860||854|
|Additional paid in capital||466,229||455,401|
|Accumulated other comprehensive loss||(14,419||)||(21,641||)|
|Total stockholders’ equity||165,102||202,984|
|Total liabilities and stockholders’ equity||$||211,299||$||281,147|
|Condensed Consolidated Cash Flow Statement|
|(unaudited, in thousands)|
| Six months ended |
|Cash flows from operating activities|
|Adjustments to reconcile net loss to net cash used in operating activities:|
|Share-based compensation expense||8,411||4,757|
|Realized loss on available-for-sale debt securities||2,473||-|
|Unrealized foreign exchange losses (gains)||2,915||(3,206||)|
|Changes in operating assets and liabilities:|
|(Increase) decrease in receivables and other operating assets||(11,602||)||2,301|
|Decrease (increase) in non-current operating assets||87||(554||)|
|Decrease in payables and deferred revenue||(24,162||)||(10,125||)|
|Net cash used in operating activities||(82,642||)||(46,448||)|
|Cash flows from investing activities|
|Acquisition of property, plant and equipment||(3,139||)||(21,188||)|
|Acquisition of intangibles||(10||)||(266||)|
|Proceeds from disposal of property, plant and equipment||-||550|
|Maturity of short-term deposits||-||22,857|
|Investment in short-term deposits||-||(18,000||)|
|Maturity or redemption of marketable securities||70,717||-|
|Investment in marketable securities||(33,556||)||(79,774||)|
|Net cash provided by (used in) investing activities||34,012||(95,821||)|
|Cash flows from financing activities|
|Proceeds from issuance of common stock, net of issuance costs $4,774||-||103,167|
|Proceeds from exercise of stock options||2,424||31|
|Net cash provided by financing activities||2,424||103,198|
|Effect of currency exchange rate changes on cash, cash equivalents and restricted cash||4,417||2,429|
|Net decrease in cash, cash equivalents and restricted cash||(41,789||)||(36,642||)|
|Cash, cash equivalents and restricted cash at start of period||88,296||162,796|
|Cash, cash equivalents and restricted cash at end of period||$||46,507||$||126,154|
Sébastien Desprez – VP, Communications and Investor Relations
T: +44 1235 430 583
M: +44 7718 453 176
Juli P. Miller, Ph.D. – Director, Investor Relations
T: +1 215 825 9310
M: +1 215 460 8920